Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Onartuzumab Alone and with Erlotinib in Solid Tumors and MET-positive NSCLC
jRCT2080221523Phase 1
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of onartuzumab in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
onartuzumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080221523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221523.